BCRX
BioCryst Pharmaceuticals, Inc. NASDAQ Listed Mar 4, 1994$8.90
Mkt Cap $1.9B
52w Low $6.00
54.6% of range
52w High $11.31
50d MA $9.09
200d MA $7.88
P/E (TTM)
7.3x
EV/EBITDA
5.8x
P/B
—
Debt/Equity
-4.0x
ROE
-221.5%
P/FCF
5.0x
RSI (14)
—
ATR (14)
—
Beta
0.69
50d MA
$9.09
200d MA
$7.88
Avg Volume
5.2M
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
4505 Emperor Boulevard · Durham, NC 27703 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | BMO | 0.07 | 1.12 | +1500.0% | 7.90 | +0.6% | +10.8% | +9.2% | +10.0% | +8.5% | +7.6% | — |
| Nov 3, 2025 | BMO | 0.07 | 0.06 | -14.3% | 6.86 | -2.3% | -1.5% | +4.5% | +2.5% | +3.4% | +5.0% | — |
| Aug 4, 2025 | BMO | 0.03 | 0.15 | +400.0% | 8.73 | -1.3% | -4.2% | -1.5% | -4.4% | -4.9% | -6.1% | — |
| May 5, 2025 | BMO | -0.07 | 0.00 | +100.3% | 11.03 | -0.5% | -6.9% | -8.6% | -10.1% | -9.6% | -6.3% | — |
| Feb 24, 2025 | BMO | -0.07 | -0.13 | -85.7% | 8.29 | +1.8% | -0.1% | +0.8% | +2.2% | +3.9% | +3.0% | — |
| Nov 4, 2024 | BMO | -0.07 | -0.07 | +0.0% | 7.35 | +0.4% | -3.9% | +5.2% | +4.4% | +5.9% | +11.4% | — |
| Aug 5, 2024 | BMO | -0.19 | -0.06 | +68.4% | 7.51 | +1.2% | +4.8% | -0.9% | +6.1% | +1.6% | +2.9% | — |
| May 6, 2024 | BMO | -0.23 | -0.17 | +26.1% | 5.27 | +2.3% | -0.2% | -3.2% | +1.3% | +0.9% | +6.8% | — |
| Feb 26, 2024 | BMO | -0.24 | -0.28 | -16.7% | 5.79 | +1.7% | +1.4% | -1.4% | -2.8% | -2.9% | -4.8% | — |
| Nov 2, 2023 | BMO | -0.25 | -0.19 | +24.0% | 5.64 | +3.0% | +7.1% | +5.1% | +7.6% | -3.0% | -11.2% | — |
| Aug 3, 2023 | BMO | -0.25 | -0.24 | +4.0% | 7.08 | +4.1% | +7.3% | -5.2% | -0.8% | -1.3% | -0.1% | — |
| May 3, 2023 | BMO | -0.30 | -0.28 | +6.7% | 8.29 | +0.7% | +2.2% | +3.3% | +2.4% | +3.5% | +4.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 30 | RBC Capital | Maintains | Outperform → Outperform | — | $6.67 | $6.61 | -0.9% | -1.3% | -0.6% | +0.4% | -3.7% | -6.4% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.57 | $7.64 | +0.9% | +0.3% | -1.3% | -5.8% | -3.7% | -2.1% |
| Nov 5 | Citizens | Maintains | Market Outperform → Market Outperform | — | $6.76 | $6.86 | +1.5% | +6.1% | +4.0% | +4.9% | +6.5% | +7.0% |
| Nov 4 | Needham | Maintains | Buy → Buy | — | $6.86 | $6.70 | -2.3% | -1.5% | +4.5% | +2.5% | +3.4% | +5.0% |
| Nov 4 | Barclays | Maintains | Equal Weight → Equal Weight | — | $6.86 | $6.70 | -2.3% | -1.5% | +4.5% | +2.5% | +3.4% | +5.0% |
| Oct 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.42 | $6.53 | +1.7% | +6.1% | +4.7% | +3.3% | +7.9% | +8.9% |
| Oct 15 | Needham | Maintains | Buy → Buy | — | $6.42 | $6.53 | +1.7% | +6.1% | +4.7% | +3.3% | +7.9% | +8.9% |
| Oct 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.42 | $6.53 | +1.7% | +6.1% | +4.7% | +3.3% | +7.9% | +8.9% |
| Aug 4 | Needham | Maintains | Buy → Buy | — | $7.95 | $9.14 | +15.0% | +9.8% | +5.2% | +8.2% | +5.0% | +4.4% |
| Jul 1 | BofA Securities | Maintains | Buy → Buy | — | $8.96 | $8.98 | +0.2% | +0.4% | +0.7% | -0.2% | -2.2% | -1.9% |
| Jun 30 | Wedbush | Maintains | Outperform → Outperform | — | $9.36 | $9.47 | +1.2% | -4.3% | -3.8% | -3.6% | -4.5% | -6.4% |
| Jun 30 | RBC Capital | Maintains | Outperform → Outperform | — | $9.36 | $9.47 | +1.2% | -4.3% | -3.8% | -3.6% | -4.5% | -6.4% |
| Jun 27 | Needham | Maintains | Buy → Buy | — | $9.66 | $10.05 | +4.0% | -3.1% | -7.2% | -6.8% | -6.6% | -7.5% |
| Jun 25 | Needham | Maintains | Buy → Buy | — | $9.93 | $9.94 | +0.1% | -1.9% | -2.7% | -5.7% | -9.8% | -9.4% |
| May 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $10.27 | $10.36 | +0.9% | -1.9% | -3.4% | -2.9% | +0.7% | -2.0% |
| May 6 | JP Morgan | Maintains | Overweight → Overweight | — | $11.03 | $10.97 | -0.5% | -6.9% | -8.6% | -10.1% | -9.6% | -6.3% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.03 | $10.97 | -0.5% | -6.9% | -8.6% | -10.1% | -9.6% | -6.3% |
| May 6 | RBC Capital | Maintains | Outperform → Outperform | — | $11.03 | $10.97 | -0.5% | -6.9% | -8.6% | -10.1% | -9.6% | -6.3% |
| May 6 | Needham | Maintains | Buy → Buy | — | $11.03 | $10.97 | -0.5% | -6.9% | -8.6% | -10.1% | -9.6% | -6.3% |
| Apr 11 | RBC Capital | Maintains | Outperform → Outperform | — | $6.41 | $6.33 | -1.2% | +6.4% | +9.8% | +15.4% | +12.6% | +15.4% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $6.77 | $6.57 | -3.0% | -5.3% | +0.7% | +4.0% | +9.3% | +6.6% |
| Mar 3 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $8.61 | $8.58 | -0.3% | -0.8% | -3.5% | -6.5% | -8.7% | -10.7% |
| Feb 25 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $8.29 | $8.44 | +1.8% | -0.1% | +0.8% | +2.2% | +3.9% | +3.0% |
| Feb 25 | RBC Capital | Maintains | Outperform → Outperform | — | $8.29 | $8.44 | +1.8% | -0.1% | +0.8% | +2.2% | +3.9% | +3.0% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.29 | $8.44 | +1.8% | -0.1% | +0.8% | +2.2% | +3.9% | +3.0% |
| Jan 31 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.87 | $7.86 | -0.1% | +0.4% | -3.2% | +2.8% | +9.4% | +10.9% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $7.67 | $7.77 | +1.3% | +3.4% | -5.7% | -5.7% | -8.0% | -2.9% |
| Jan 13 | Evercore ISI | Maintains | Outperform → Outperform | — | $7.67 | $7.77 | +1.3% | +3.4% | -5.7% | -5.7% | -8.0% | -2.9% |
| Dec 17 | Needham | Maintains | Buy → Buy | — | $7.46 | $7.23 | -3.1% | +0.4% | -2.0% | -0.9% | +1.5% | +4.3% |
| Nov 5 | RBC Capital | Maintains | Outperform → Outperform | — | $7.35 | $7.38 | +0.4% | -3.9% | +5.2% | +4.4% | +5.9% | +11.4% |
| Nov 5 | Needham | Maintains | Buy → Buy | — | $7.35 | $7.38 | +0.4% | -3.9% | +5.2% | +4.4% | +5.9% | +11.4% |
| Nov 5 | Barclays | Maintains | Equal Weight → Equal Weight | — | $7.35 | $7.38 | +0.4% | -3.9% | +5.2% | +4.4% | +5.9% | +11.4% |
| Aug 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.51 | $7.60 | +1.2% | +4.8% | -0.9% | +6.1% | +1.6% | +2.9% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.51 | $7.60 | +1.2% | +4.8% | -0.9% | +6.1% | +1.6% | +2.9% |
| Aug 6 | RBC Capital | Maintains | Outperform → Outperform | — | $7.51 | $7.60 | +1.2% | +4.8% | -0.9% | +6.1% | +1.6% | +2.9% |
| Aug 6 | Barclays | Maintains | Equal Weight → Equal Weight | — | $7.51 | $7.60 | +1.2% | +4.8% | -0.9% | +6.1% | +1.6% | +2.9% |
| May 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.27 | $5.39 | +2.3% | -0.2% | -3.2% | +1.3% | +0.9% | +6.8% |
| May 7 | Needham | Maintains | Buy → Buy | — | $5.27 | $5.39 | +2.3% | -0.2% | -3.2% | +1.3% | +0.9% | +6.8% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.27 | $5.39 | +2.3% | -0.2% | -3.2% | +1.3% | +0.9% | +6.8% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $4.80 | $4.64 | -3.3% | +1.5% | +6.2% | -0.6% | -2.7% | -4.0% |
| Jan 8 | Needham | Maintains | Buy → Buy | — | $6.09 | $6.30 | +3.4% | +25.6% | +22.2% | +13.0% | +6.2% | +4.3% |
| Nov 6 | Needham | Maintains | Buy → Buy | — | $6.04 | $6.19 | +2.5% | -1.8% | +0.5% | -9.4% | -17.1% | -17.5% |
| Sep 25 | RBC Capital | Maintains | Outperform → Outperform | — | $7.35 | $7.30 | -0.7% | +0.3% | +0.0% | +2.3% | -1.5% | -3.7% |
| Sep 18 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $6.85 | $7.20 | +5.1% | +9.9% | +11.7% | +3.8% | +4.5% | +7.3% |
| Aug 4 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $7.08 | $7.37 | +4.1% | +7.3% | -5.2% | -0.8% | -1.3% | -0.1% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.08 | $7.37 | +4.1% | +7.3% | -5.2% | -0.8% | -1.3% | -0.1% |
| Aug 4 | Jefferies | Upgrade | Hold → Buy | — | $7.08 | $7.37 | +4.1% | +7.3% | -5.2% | -0.8% | -1.3% | -0.1% |
| Jul 13 | BofA Securities | Upgrade | Neutral → Buy | — | $7.18 | $7.65 | +6.5% | +2.4% | -0.7% | +0.1% | -0.1% | +2.5% |
| May 4 | Needham | Maintains | Buy → Buy | — | $8.29 | $8.35 | +0.7% | +2.2% | +3.3% | +2.4% | +3.5% | +4.1% |
| May 4 | RBC Capital | Maintains | Sector Perform → Perform | — | $8.29 | $8.35 | +0.7% | +2.2% | +3.3% | +2.4% | +3.5% | +4.1% |
No insider trades available.
8-K · 2.02
!! High
BioCryst Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
BioCryst Pharmaceuticals reported quarterly earnings results, with detailed financial performance and operational updates available in the accompanying press release exhibit.
May 6
8-K · 7.01
! Medium
BioCryst Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
BioCryst Pharmaceuticals secured $70 million upfront plus up to $275 million in milestones by granting exclusive European commercialization rights for navenibart to treat hereditary angioedema.
May 4
8-K
Tenax Therapeutics, Inc. -- 8-K Filing
Tenax Therapeutics' CFO previously led Triangle Pharmaceuticals through its acquisition by Gilead Sciences, demonstrating experience navigating pharma M&A transactions that could benefit Tenax shareholders.
Apr 22
8-K · 7.01
! Medium
BioCryst Pharmaceuticals Inc -- 8-K 7.01: Regulation FD Disclosure
BioCryst Pharmaceuticals disclosed material information via Exhibit 99.1, requiring investors to review the attached document for potentially significant developments affecting the company's financial position or operations.
Feb 26
Data updated apr 24, 2026 8:57pm
· Source: massive.com